Potential impacts of GLP-1 drugs should be considered as key risks to Resmed investment thesis. However, the likely impact is overstated, or over-priced into the share price. Resmed is trading at 18 times their FY25 forecast compared to the 10-year average of 28 times.
Potential impacts of GLP-1 drugs should be considered as key...
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$32.85 |
Change
0.265(0.81%) |
Mkt cap ! $20.38B | |||
| Open | High | Low | Value | Volume |
| $32.85 | $32.97 | $32.73 | $107.9M | 3.291M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 823 | $32.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $32.85 | 4652 | 40 |
View Market Depth
| Last trade - 15.04pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$32.89 |
Change
0.265 ( 1.04 %) |
||||
| Open | High | Low | Volume | ||
| $32.85 | $32.96 | $32.74 | 439286 | ||
| Last updated 15.25pm 30/04/2024 ? | |||||
| RMD (ASX) Chart |